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BACKGROUND: Primary dysmenorrhea is common among women of (1.4; 95% CI, 2.0 to 0.8; P < .001) reached clinical relevance. At
reproductive age. Nonsteroidal anti-inflammatory drugs and oral contra-
ceptives are effective treatments, although the failure rate is around 20%
to 25%. Therefore additional evidence-based treatments are needed. In
recent years, the use of smartphone applications (apps) has increased
rapidly and may support individuals in self-management strategies.
OBJECTIVE: We aimed to investigate the effectiveness of app-based
self-acupressure in women with menstrual pain.
MATERIALS AND METHODS: A 2-armed, randomized, pragmatic
trial was conducted from December 2012 to April 2015 with recruitment
until August 2014 in Berlin, Germany, among women aged 18 to 34 years
with self-reported cramping pain of 6 or more on a numeric rating scale
(NRS) for the worst pain intensity during the previous menstruation. After
randomization, women performed either app-based self-acupressure
(n ¼ 111) or followed usual care only (n ¼ 110) for 6 consecutive
menstruation cycles. The primary outcome was the mean pain intensity
(NRS 010) on the days with pain during the third menstruation. Sec-
ondary outcomes included worst pain intensity during menstruation,
duration of pain, 50% responder rates (reduction of mean pain by at least
50%), medication intake, sick leave days, and body efficacy expectation
assessed at the first, second, third, and sixth menstruation cycles.
RESULTS: We included 221 women (mean age, 24.0 years; standard
deviation [SD], 3.6 years). The mean pain intensity difference during the
third menstruation was statistically significant in favor of acupressure
(acupressure: 4.4; 95% confidence interval [CI], 4.04.7; usual care 5.0;
95% CI, 4.65.3; mean difference 0.6; 95% CI,  1.2 to 0.1;
P ¼ .026). At the sixth cycle, the mean difference between the groupsCite this article as: Blo¨dt S, Pach D, von Eisenhart-Rothe S,
et al. Effectiveness of app-based self-acupressure for
women with menstrual pain compared to usual care: a
randomized pragmatic trial. Am J Obstet Gynecol
2018;218:227.e1-9.
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https://doi.org/10.1016/j.ajog.2017.11.570the third and sixth menstruation cycles, responder rates were 37% and
58%, respectively, in the acupressure group, in contrast to 23% and 24%
in the usual care group. Moreover, the worst pain intensity (group
difference 0.6; 95% CI, 1.2 to 0.02; and 1.4; 95% CI, 2.0
to 0.7), the number of days with pain (0.4; 95% CI, 0.9 to 0.01;
and1.2; 95% CI,1.6 to0.7) and the proportion of women with pain
medication at the third and sixth menstruation cycles (odds ratio [OR], 0.5;
95% CI, 0.30.9] and 0.3 (95% CI, 0.20.5) were lower in the
acupressure group. At the third cycle, hormonal contraceptive use was
more common in the usual care group than in the acupressure group (OR,
0.5; 95% CI, 0.30.97) but not statistically significantly different at the
sixth cycle (OR, 0.6; 95% CI, 0.31.1]). The number of sick leave days
and body efficacy expectation (self-efficacy scale) did not differ between
groups.
On a scale of 0 to 6, mean satisfaction with the intervention at the third
cycle was 3.7 (SD 1.3), recommendation of the intervention to others 4.3
(1.5), appropriateness of acupressure for menstrual pain 3.9 (1.4), and
application of acupressure for other pain 4.3 (1.5). The intervention was
safe, and after the sixth cycle, two-thirds of the women (67.6%) still
applied acupressure on all days with pain.
CONCLUSION: Smartphone appdelivered self-acupressure resulted
in a reduction of menstrual pain compared to usual care only. Effects were
increasing over time, and adherence was good. Future trials should
include comparisons with other active treatment options.
Key words: acupressure, dysmenorrhea, mHealth, painrimary dysmenorrhea1 affects up toP 81% of women of reproductive
age,2,3 with approximately 15% experi-
encing severe pain.2Menstrual pain has a
relevant impact on quality of life4 and
results in a substantial economic loss.5,6Nonsteroidal anti-inﬂammatory drugs
and oral contraceptives are effective
treatments,7 although the failure rate is
around 20% to 25%5,8,9 because of side
effects7,10 and lack of effectiveness in
some cases.10-12 Additional evidence-
based treatments are needed.13 Of
women with menstrual pain, 70% are
reported to practice self-management.10
A few studies have investigated the effect
of self-acupressure for dysmenorrhea,
mostly as an add-on to therapist-
administered acupressure.13-16 Although
results showed a beneﬁcial effect for self-
acupressure,17-21 the evidence is unclear
due to risk of bias (mostly due to perfor-
mance and attrition bias).13FEBRUARY 2018 AmeriIn recent years, the use of smartphone
applications (apps)22 has increased
rapidly. Mobile and electronic health
solutions are already widely used in
the general public and are seen as a
valuable tool for various health
problems22-25 and self-management.26
Mobile health (mHealth) solutions
might have improved the autonomy and
participation of users already,26 for
example by facilitating the search for
information and health services, as well
as by structuring of information and
data. Health data is increasingly being
collected via smartphones and portable
devices (so-called wearables) and can be
shared with doctors and other servicecan Journal of Obstetrics& Gynecology 227.e1
Original Research GYNECOLOGY ajog.orgproviders. Individual behavior can be
positively inﬂuenced with the help of
behavioral change techniques and used,
for example, for smoking cessation or
weight control.27,28 Only a few mHealth
solutions have been investigated in ran-
domized controlled trials to date, and the
majority of available apps do not report
any health care professional involvement
in their development22,25 Nevertheless, a
strong increase inmHealth solutions and
increasing integration into usual care is
expected. App-based self-acupressure
might be innovative to support women
with menstrual pain; however, its effec-
tiveness in a usual care setting remains
unclear.
In this study, we aimed to investigate
whether app-based self-acupressure is
more effective in reducing pain thanusual
care for women with menstrual pain.
Materials and Methods
Study design
We performed a 2-armed, randomized,
pragmatic trial with a treatment
duration and observation time of 6
menstruation cycles per woman. The
design of the trial and the development
of the smartphone app “AKUD” were
shaped by stakeholder engagement
(see previous publication29). A statisti-
cian not involved in the study used
“ranuni” random number generator
of the SAS/STAT software version 9.2
(SAS Institute, Cary, NC) to generate the
randomization list (1:1 ratio). The list
was transferred into a secured database
(Microsoft Ofﬁce Access 2010; Microsoft
Corporation, Redmond, WA) and hid-
den behind the interface so that it was
not accessible to anyone involved in the
random allocation or treatment. Eligible
women were randomized by clicking a
button of the database interface. The
result could not be changed, which
ensured allocation concealment.
This study followed the standards of
the Declaration of Helsinki30 and the
International Council for Harmonisation
of Technical Requirements for Pharma-
ceuticals for Human Use good clinical
practice (ICH-GCP) guidelines, and were
approved by the respective Ethics Com-
mittee (CharitéUniversitätsmedizin
Berlin EA1/027/12). All patients gave oral227.e2 American Journal of Obstetrics& Gynecoland written informed consent. The trial
was registered at clinicaltrials.gov
(NCT01582724), and the study protocol
was published.29
Participants and setting
Women were recruited in Berlin,
Germany, from December 2012 to
August 2014, using information mate-
rials (posters, ﬂyers, and leaﬂets),
the intranet platforms of Char-
itéUniversitätsmedizin Berlin, and
students’ e-mail lists. In adition,
the study was advertised on 2 Berlin
subway lines for 5 months. Telephone
interviews were used for participant
prescreening. To facilitate recruitment,
a ﬁnancial compensation of 30 EUR
was introduced after 8 months.
Participants were eligible for the trial
if they fulﬁlled the following inclusion
criteria: female sex; 18 to 25 years of age
(criterion broadened to 1834 years af-
ter 8 months of recruitment to facilitate
recruitment); having dysmenorrhea,
deﬁned as self-reported cramping pain
during every menstrual cycle; no prior
history of a gynecologic disease that
could be a reason for dysmenorrhea;
having had menstruation in the last
6 weeks and a menstrual cycle duration
between 3 and 6 weeks; moderate or
severe pain, deﬁned as a score equal to or
greater than 6 on a numeric rating scale
(NRS, 010) for the worst pain intensity
during the last menstruation; and
providing written and oral informed
consent. Participants had to own a
smartphone (iOS or Android) and to
agree to enter study data through the
app. Patients were not eligible for the
trial if they fulﬁlled any of the following
exclusion criteria: already using or
planning to use acupressure, acupunc-
ture, shiatsu, or/and tuinamassage in the
following 8 months; or known preg-
nancy or planned pregnancy in the
following 8 months.
Intervention and control group
Both treatment groups received the app
AKUD (Software development: Smart
Mobile Factory, Berlin, Germany),
which included a visualization of the
menstrual cycle, questionnaires, and
diaries for both groups.ogy FEBRUARY 2018Acupressure speciﬁc features were
available only for the acupressure
group. These included explanations of
the acupressure procedure, drawings,
videos, and photos of the acupressure
points, as well as a timer to guide the
1-minute acupressure of each point.
The acupressure intervention (points,
duration, setting) resulted from awritten
Delphi consensus with international
acupuncture experts from China,
Germany, and the United States.29 The
acupuncture points SP6 (Sanyinjiao),
LI4 (Hegu), and LR3 (Taichong) were
used on both sides. In the acupressure
group, a health care professional intro-
duced the acupressure based on the
instruction of the app at the baseline visit
(Table 1). The womenwere reminded by
the app every noon to apply acupressure
starting 5 days before the anticipated
menstruation. Users could switch off
the reminders within the app. To keep
the intervention standardized, the app
received no major updates.
Women in the control group did not
receive any study speciﬁc intervention.
After the sixth menstruation cycle,
that is, at the end of the study, the
acupressure features were activated
within the app and a personal face-to-
face introduction to acupressure was
offered.
The acupressure and the control
groups could continue with usual care
during the study, which was deﬁned as
all medical and nonmedical treatments
with the exception of tuina, shiatsu,
and acupuncture because of the use of
similar pressure points.
Outcome measurements
The primary outcome measure was the
mean pain intensity on the days with
pain during the third menstruation on a
numerical rating scale (NRS) from
0 (no pain) to 10 (worst possible pain)
assessed retrospectively after the third
menstruation.31 The NRS and the time
point were chosen based on the stake-
holder process in preparation of the
trial29 and previous literature on
acupressure on dysmenorrhea.14 The
NRS is easy to apply and well suited for
implementation in a smartphone app,
and 3 months seemed long enough to
TABLE 1
Instructions for applying acupressure
Carrying out acupressure
Find a comfortable sitting position. The right point will feel more sensitive than the surrounding
area, and you may feel a slight soreness. When you have found the point, massage the area
with the thumb using medium force (strong enough, but not so strong that you injure yourself) in
small circles. Pay attention that you use circular movements and do not rub back and forth.
While massaging, you should notice a distinct sensation, for example, a slight soreness,
tingling, hypersensitivity, or heaviness.
Method
Concentrate on the points as you are massaging them. Massage the points on both sides
consecutively for 1 minute each. Start the timer.
Application
Begin 5 days before you get your period. As a function of the app, you will receive a reminder of
when you should begin the acupressure. Before your menstrual period, carry out the
acupressure twice a day if possible; on days when this is not possible, carry out the
acupressure at least once a day. During your period, on the painful days carry out the
acupressure at least twice a day. If you like, you can repeat the acupressure up to 5 times.
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effect without risking recruitment or
study adherence because of a relatively
long study duration.
Secondary outcomes were assessed
during and after the ﬁrst, second, third,
and sixth menstruation cycle by the app
in both groups. These outcomes
included worst pain intensity during
menstruation (NRS), duration of pain
(number of days with pain), responder
rates (50% reduction of mean pain in-
tensity on the days with pain compared
to the corresponding baseline value),
pain medication, sick leave (days of
absence from work or school due to
menstrual pain), body efﬁcacy expecta-
tion,32 adverse events, and suspected
adverse reactions (intervention group
only). Women in the acupressure group
were also asked at the third cycle about
satisfaction with the intervention. On
the days on which acupressure was rec-
ommended, women were asked to re-
cord the number of acupressure sessions
and the time that they spent for the
acupressure.
At baseline, self-reported data were
collected by paper and pencil. All
other questionnaires and diaries were
embedded into the app. Most outcomes
were collected by questionnaires within
the app at the end of the menstruation;
however, data on pain medication andtime spent for acupressure were
collected by the app’s diary.Womenwere
reminded by app notiﬁcations every day
at noon during the menstruation to ﬁll
in the questions of the diary. In addition,
they were reminded at the respective
time point to complete the question-
naires at the last day of menstruation at
the ﬁrst, second, third, and sixth men-
struations. In the acupressure group, this
notiﬁcation was combined with the
reminder to apply acupressure.
Statistical analysis
The studywas designed to detect an effect
size of 0.5 for the primary outcome
measure (menstrual pain), with a power
of 90% and a signiﬁcance level of 5%
using a 2-sided t test. Based on previous
acupuncture studies, we assumed a mean
of 5.5 in the control group and 4.0 in the
intervention group, with a pooled stan-
dard deviation of 3 resulting in a total of
86 participants per group. Taking a
potential drop-out rate of about 20% into
account, 220 participants (110 per group)
were planned. The primary analysis
population was the full analysis set (FAS,
with available data for the respective
analysis) based on the intention-to-treat
(ITT) principle of including each
woman into the analysis according to her
randomization group regardless of her
adherence to the assigned intervention.FEBRUARY 2018 AmeriThe primary analysis of the primary
endpoint was an analysis of covariance
(ANCOVA) with the treatment as a ﬁxed
effect, the baseline NRS value as ﬁxed
covariate, and a 2-sided signiﬁcance level
of 5%. Secondary outcomes were
analyzed similarly, that is, by ANCOVA
or by logistic or Poisson regression
(depending on the scale and distribution
of the data), adjusted for the respective
baseline value (if available).
As a sensitivity analysis, multiple
imputation techniques were performed
using Markov Chain Monte Carlo
approximation and fully conditional
speciﬁcation (FCS) methods.33 The
imputationmodel included all variables
for the primary and secondary out-
comes and age. Furthermore, in case of
relevant differences in baseline vari-
ables between the treatment groups,
those unbalanced variables were used
as covariates for the analysis of the
primary outcome. In addition, we
evaluated the subgroups of women with
hormonal contraceptive use at baseline,
women with a migration background,
and womenwith age of 26 years or more
versus less than 26 years. Subgroups
were evaluated using the interaction
term of the respective subgroup with
the treatment group in the analysis
model.
As further supportive analysis, mixed
models for repeated measures (MMRM)
were ﬁtted to compare the treatment
groups with respect to changes in the
primary outcome over time. The model
included terms for treatment (acupres-
sure vs control) and time as ﬁxed main
effects, an interaction term for treatment
by time, the baseline value as covariate,
and the subject as a random effect.
Analysis was done using SPSS 21.0




The study was conducted between
December 2012 and April 2015, with
recruitment from December 2012 until
August 2014.
Of 446 screened women, 221 were
eligible for the study, gave consent,
and were randomized either tocan Journal of Obstetrics& Gynecology 227.e3
FIGURE 1
Trial flow chart.
111 Allocated to Acupressure 110 Allocated to Usual care
108 Follow-up at cycle 1
1 scheduling problems  
1 pregnancy
1 no menstruation anymore
109 Follow-up at cycle 1
1 diagnosed with endometriosis
106 Follow-up at cycle 2
1 no smartphone anymore
1  without giving reasons
107 Follow-up at cycle 2
1 scheduling problems
1 pregnancy
102 Follow-up at cycle 3
2  no contact
1 no smartphone anymore
1  without giving reasons
107 Follow-up at cycle 3
95 Follow-up at cycle 6
2 no further interest
1  scheduling problems
1  lost contact
1 no menstruation anymore
1 pregnancy
1 without giving reasons
105 Follow-up at cycle 6
2 without giving reasons
102 used for primary endpoint analysis   
based on ITT*
107 used for primary endpoint analysis 
based on ITT 


























446 assessed for eligibility
224 excluded  
48 too old or too young
39 worst pain intensity too low
16 declined to participate
39 no Android phone or no iPhone
15 other criteria
222 enrollment visit
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care (n¼110)(Figure 1).
The women had a mean age of 24.0
years (standard deviation [SD], 3.6
years) and were highly educated, with
89.6% having 12 or more years of school
education (Table 2). A total of 37 women
(16.7%) had a migration background.
At baseline, the mean pain intensity on
the days with pain on the NRS was 6.2
(SD, 1.6) and most women (81.0%) had
taken medication during their last
menstruation. The following group227.e4 American Journal of Obstetrics& Gynecoldifferences with possible relevance were
seen at baseline: fewer women in the
usual care group (65.1%) had a partner
(acupressure group 78.4%), and more
women in the usual care group used oral
contraceptives (36.4% vs 23.4%).
Outcomes
Both groups showed a reduction in pain
at the third and sixthmenstruation cycle.
The primary outcome measurement
(mean pain intensity on the days of pain
during the third cycle after therapy start)ogy FEBRUARY 2018showed a statistically signiﬁcant differ-
ence in favor of the acupressure group
(acupressure: 4.4; 95% CI, 4.04.7;
usual care: 5.0; 95% CI, 4.65.3; mean
difference, 0.6; 95% CI, 1.2 to 0.1;
P ¼ .026 (Table 3 and Figure 2). At the
sixth menstruation cycle, the mean dif-
ference between the groups increased
(1.4; 95% CI, 2.0 to 0.8; P < .001)
and was considered clinically relevant.34
The effect size (Cohen’s d) for the
mean pain intensity was 0.24 at the third
cycle and 0.63 at the sixth cycle. More-
over, the chance to be a responder was
higher for women in the acupressure
group after the ﬁrst, the third, and
the sixth cycle with odds ratios of 2.3
(95% CI, 1.05.2), 2.0 (1.13.6), and
4.4 (2.57.9), respectively.
At the third and sixth menstruation
cycle the worst pain intensity (group
difference,0.6, 95%CI,1.2 to0.02,
and 1.4, 95% 2.0 to 0.7), the
number of days with pain (0.4; 95%
CI, 0.9 to 0.01, and 1.2; 95%
CI,1.6 to0.7), and the proportion of
women with pain medication (odds
ratio, 0.5; 95%CI, 0.30.9, and 0.3; 95%
CI, 0.20.5]) was lower in the acupres-
sure group. Hormonal contraceptive use
was more common in the usual care
group than in the acupressure group at
the third cycle (odds ratio, 0.5; 95%
CI, 0.30.97), but not statistically
signiﬁcant different at the sixth cycle
(odds ratio, 0.6; 95% CI, 0.31.1). The
number of sick leave days and body
efﬁcacy expectation (self-efﬁcacy scale)
did not differ between groups (Table 3).
On a scale from 0 to 6, the mean
satisfaction with the intervention at
the third cycle was 3.7 (SD, 1.3), recom-
mendation of the intervention to
others (4.3; SD, 1.5), appropriateness of
acupressure for menstrual pain (3.9;
SD, 1.4); and application of acupressure
for other pain (4.3; SD, 1.5).
Findings were similar, and no relevant
difference between results of primary,
sensitivity, and subgroup analyses could
be observed. The baseline characteristics
of women in both groups who dropped
out before the third menstruation cycle
did not differ relevantly from those who
did not drop out.
TABLE 2
Baseline demographic and clinical characteristics of trial groups
Characteristic
Acupressure (n ¼ 111),
mean  SD/n (%)
Usual care (n ¼ 110),
mean  SD/n (%)
Age (y) 24.4  3.3 23.7  3.9
BMI (kg/m2) 22.0  3.8 21.8  3.1
12 Years of school 98 (88.3) 100 (90.9)
Size of household
Single-person 17 (15.3) 20 (18.2)
Multi-person 94 (84.7) 90 (81.8)
Partnership 87 (78.4) 71 (65.1)
Migrant background [40]a 20 (18.0) 17 (15.5)
Smartphone operating
system
iOS 45 (40.5) 38 (34.5)
Android 65 (58.6) 71 (64.5)
Duration of cycle (days) 28.7  2.7 28.7  2.5
Duration of menstruation
(days)
5.4  1.4 5.2  1.0
Concomitant diseases 13 (11.7) 5 (4.5)
Complaints/painb
Abdominal cramps 98 (88.3) 88 (80.0)
Pain in lower abdomen 97 (87.4) 83 (75.5)
Back Pain 70 (63.1) 72 (65.5)
Headache 39 (35.1) 33 (30.0)
Nausea/vomiting 35 (31.5) 30 (27.3)
Other 31 (27.9) 40 (36.4)
Hormonal contraceptive 26 (23.4) 40 (36.4)
Sick leave days 0.6  0.7 0.5  0.7
Sport/Therapy against pain 41 (36.9) 48 (43.6)
Jogging 16 (14.4) 16 (14.5)
Fitness/gymnastics 13 (11.7) 20 (18.2)
Yoga 12 (10.8) 12 (10.9)
Meditation/relaxation 9 (8.1) 7 (6.4)
Dancing 2 (1.8) 8 (7.3)
Other 16 (14.4) 26 (23.6)
Mean pain (NRS 010)c 6.3  1.6 6.1  1.6
Worst pain (NRS 010)c 7.6  1.1 7.5  1.1
Number of days with pain 2.6  1.2 2.7  1.1
Pain medication intake 89 (80.2) 90 (81.8)
Body efficacy expectation 2.8  0.5 2.8  0.5
BMI, body mass index; NRS, numeric rating scale.
a Determination by assessment of primary language, place of birth, and place of mother’s and father’s birth; b Multiple answers
possible; c Higher values indicate worst possible pain.
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In the self-acupressure group, 15 women
reported having had at least 1 suspected
adverse reaction (SAR). Over all cycles,
the following SARs were mentioned:
bruises (n ¼ 5), deterioration (n ¼ 3),
pain in the hand (n ¼ 1), pressure pain
(n ¼ 1), shift in menstruation cycle
(n ¼ 3), dizziness (n ¼ 1), nausea
(n ¼ 1), pain in the legs (n ¼ 1), and
tingling in a ﬁnger (n¼ 2). Of those who
mentioned a SAR, 10 women experi-
enced a SAR at 1 cycle, 3 women at
2 cycles, and 2 women at 3 cycles. With
the exception of 1 woman, all continued
to apply self-acupressure. This woman
stopped applying self-acupressure at the
sixth cycle because of bruises, pressure
pain, and tightness in the breast. She
had already mentioned pressure pain
at the ﬁrst cycle, which had made it
difﬁcult to continue self-acupressure,
although she did not report any SAR
at the second and third cycles.
Two serious adverse events occurred
in each treatment group (self-acupres-
sure: hip surgery, hospitalization due to
dizziness; usual care: surgery of the
nose, appendix surgery). None was
considered related to the trial or the
trial intervention.
Adherence and practice time
Overall adherence was good, but
declined slightly over time. At the ﬁrst
cycle, 108 (97.3%) of the women stated
that they had practiced acupressure on at
least 1 day during the menstruation
cycle, and at the sixth cycle this number
was 92 (82.9%). Fewer women practiced
acupressure on all days with pain (ﬁrst
cycle 102 [91.9%]; second cycle 89
[80.1%]; third cycle 91 [82.0%]; and
sixth cycle 75 [67.6%]). The mean
duration of 1 practice session was similar
over all cycles (ﬁrst cycle: before
menstruation, 5.3 minutes (mean;
SD, 2.1); during menstruation, 5.4 (SD,
1.7); sixth cycle: before menstruation,
5.4 (SD, 1.5); during menstruation, 5.3
(SD, 1.5) (Table 3). Women spent about
82.5 minutes (95% CI, 73.291.7) for
acupressure during the ﬁrst cycle, and
78.8 minutes (95% CI, 68.888.8), 76.8
minutes (67.386.4), and 68.7 minutesFEBRUARY 2018 American Journal of Obstetrics& Gynecology 227.e5
TABLE 3








vs usual care, mean
(95% CI)/OR (95% CI) P
Mean pain intensity during third
menstruation cycle (NRS)
[primary outcome]
4.4 (4.0e4.7) 5.0 (4.6e5.3) e0.6 (e1.2 to e0.1) .026
Mean pain intensity (NRS)
First cycle 4.9 (4.5e5.2) 5.2 (4.9e5.5) e0.3 (e0.8 to 0.1) .171
Second cycle 4.6 (4.2e5.0) 4.9 (4.5e5.3) e0.4 (e0.9 to 0.2) .197
Sixth cycle 3.5 (3.1e4.0) 5.0 (4.5e5.4) e1.4 (e2.0 to e0.8) <.001
Worst pain intensity
First cycle 6.2 (5.9e6.6) 6.4 (6.1e6.8) e0.2 (e0.7 to 0.3) .383
Second cycle 5.8 (5.4e6.2) 6.1 (5.7e6.5) e0.3 (e0.8 to 0.3) .374
Third cycle 5.6 (5.2e6.0) 6.2 (5.8e6.6) e0.6 (e1.2 to e0.02) .043
Sixth cycle 4.9 (4.4e5.4) 6.3 (5.8e6.8) e1.4 (e2.0 to e0.7) <.001
Number of days with pain
First cycle 2.7 (2.4e3.0) 2.8 (2.4e3.1) e0.05 (e0.5 to 0.4) .828
Second cycle 2.3 (2.0e2.6) 3.1 (2.8e3.4) e0.8 (e1.2 to e0.3) .001
Third cycle 2.3 (2.0e2.6) 2.7 (2.4e3.0) e0.4 (e0.9 to e0.01) .047
Sixth cycle 1.9 (1.6e2.2) 3.1 (2.7e3.4) e1.2 (e1.6 to e0.7) <.001
Women with pain
medication intakea,b
First cycle 0.5 (0.4e0.6) 0.7 (0.6e0.8) 0.4 (0.2e0.8) .004
Second cycle 0.6 (0.5e0.7) 0.7 (0.6e0.8) 0.6 (0.3e0.1) .051
Third cycle 0.6 (0.5e0.7) 0.7 (0.6e0.8) 0.5 (0.3e0.9) .029
Sixth cycle 0.5 (0.4e0.6) 0.8 (0.7e0.8) 0.3 (0.2e0.5) <.001
Number of days with
pain medication
First cycle 1.2 (1.0e1.4) 1.4 (1.2e1.6) e0.2 (e0.6 to 0.1) .110
Second cycle 1.1 (0.9e1.3) 1.5 (1.3e1.8) e0.4 (e0.7 to e0.1) .015
Third cycle 1.1 (0.9e1.3) 1.5 (1.2e1.7) e0.4 (e0.7 to e0.1) .021
Sixth cycle 0.9 (0.7e1.0) 1.6 (1.4e1.9) e0.7 (e1.1 to e0.4) <.001
Women with hormonal
contraceptivesa,b
First cycle 0.3 (0.2e0.3) 0.3 (0.3e0.4) 0.6 (0.3e1.1) .116
Second cycle 0.2 (0.2e0.3) 0.3 (0.3e0.4) 0.6 (0.3e1.1) .088
Third cycle 0.2 (0.2e0.3) 0.4 (0.3e0.5) 0.5 (0.3e0.97) .040
Sixth cycle 0.2 (0.2e0.3) 0.4 (0.3e0.5) 0.6 (0.3e1.1) .084
General change in
menstrual painc
Third cycle 2.1 (1.9e2.2) 2.8 (2.6e2.9) e <.001
Sixth cycle 1.8 (1.7e2.0) 2.8 (2.7e3.0) e <.001
Responder ratea,b,d
First cycle 0.2 (0.1e0.3) 0.1 (0.05e0.2) 2.3 (1.0e5.2) .040
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vs usual care, mean
(95% CI)/OR (95% CI) P
Second cycle 0.3 (0.2e0.4) 0.2 (0.2e0.3) 1.6 (0.9e3.0) .109
Third cycle 0.4 (0.3e0.5) 0.2 (0.2e0.3) 2.0 (1.1e3.6) .023
Sixth cycle 0.6 (0.5e0.7) 0.2 (0.2e0.3) 4.4 (2.5e7.9) <.001
Sick leave days
First cycle 0.3 (0.2e0.4) 0.3 (0.2e0.4) 0.04 (e0.1 to 0.2) .497
Second cycle 0.2 (0.1e0.3) 0.2 (0.1e0.3) 0.01 (e0.1 to 0.1) .854
Third cycle 0.3 (0.2e0.4) 0.3 (0.2e0.4) e0.01 (e0.1 to 0.1) .870
Sixth cycle 0.2 (0.1e0.3) 0.2 (0.2e0.3) e0.1 (e0.2 to 0.04) .250
Body efficacy expectation
First cycle 2.8 (2.8e2.9) 2.9 (2.8e2.9) e0.02 (e0.1 to 0.1) .629
Second cycle 2.8 (2.7e2.9) 2.8 (2.7e2.9) 0.02 (e0.1 to 0.1) .698
Third cycle 2.9 (2.8e3.0) 2.8 (2.7e2.9) 0.1 (e0.04 to 0.2) .195
Sixth cycle 2.9 (2.8e3.0) 2.8 (2.7e2.9) 0.05 (e0.1 to 0.2) .424
CI, confidence interval; NRS, numeric rating scale; OR, odds ratio.
a Proportion (95% CI); b Odds ratio; c Scale of 15 (menstrual pain had: 1 ¼ improved significantly, 2 ¼ improved slightly, 3 ¼ no change, 4 ¼ worsened slightly, 5 ¼ worsened significantly);
d Responder rate ¼ mean pain reduced by at least 50%.
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sixth cycle, respectively.
Comment
Participating women with menstrual
pain who applied self-acupressure sup-
ported by a smartphone app experi-
enced statistically signiﬁcant different
pain relief after 3 menstruation cycles in
comparison to women who received
usual care. After 6 menstruation cycles,
in the intervention group pain further
decreased, resulting in a clinically rele-
vant difference between groups.
The strengths of this trial include the
randomized study design, the large
number of participants for an interven-
tional randomized trial on acupressure,
and the high adherence and follow-up
rates. By using a smartphone app for
the delivery of the intervention and for
data collection, the trial used a novel
study approach. Moreover, we consider
the results to be transferrable to standard
care settings, because this pragmatic trial
resulted from an extensive stakeholder
engagement process.29However, the results of our trial might
have been inﬂuenced by the selection of
our sample. Although we aimed at a
diverse sample by advertising on public
transportation, almost 90% percent of
participants had at least 12 years of school
education, which is more than the
average population. Furthermore, one-
third of the screened women failed
eligibility criteria. These aspects do affect
the generalizability of the results. Our
outcome assessment was reduced to a
minimum29 because stakeholders sug-
gested that the outcome assessment
should be short and patient-relevant, and
that data should be collected by an app.
The whole trial duration, including the
preparation for the app, took 4.5 years,
which is a long time for a trial on con-
sumer technology.35 In contrast, a longer
follow-up timemight have providedmore
insight about long-term use. Based on the
development of the primary outcome
over time, a longer follow-up might have
shown an even higher effect. However,
due to the relatively short follow-up
time, it is also possible that we haveFEBRUARY 2018 Amerioverestimated the impact of treatment.
Recruitment for this trial was difﬁcult,
and a longer study duration might
have had a further inhibiting impact on
recruitment. For future studies, ways to
accelerate recruitment are needed. To
keep the intervention standardized, our
app received no major updates. However,
an advanced development of the app for
future studies is already in progress.
Considering the large number of
available mobile Health (mHealth) apps
for smartphones, only a few have been
evaluated in an randomized controlled
trial setting.27,28,36,37 To our knowledge,
no randomized controlled trial evalu-
ating a smartphone app using acupres-
sure or targeting menstrual pain had
previously been conducted. According
to the updated Cochrane Review
“Acupuncture for dysmenorrhoea,”
which included acupressure trials, evi-
dence is insufﬁcient to demonstrate
whether or not acupuncture or
acupressure is effective in treating pri-
mary dysmenorrhea because of the
methodological limitations of thecan Journal of Obstetrics& Gynecology 227.e7
FIGURE 2
Mean pain intensity (unadjusted mean, 95% confidence interval).
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Original Research GYNECOLOGY ajog.orgincluded studies.13 Although our
rigorously designed trial might support
the evidence base in favor of acupres-
sure, it might also be associated with a
high risk of bias because of the lack of
blinding.38 However, we think that our
trial can contribute valuable data to its
effectiveness in usual care.
Our results might have practical
implications, because they could add a
self-care option to the recommended
treatment options of oral contraceptives
and nonsteroidal anti-inﬂammatory
drugs, which are effective but have lim-
itations because of associated side ef-
fects7,10 and failure rates.5 Moreover,
self-care treatments such as rest, medi-
cation, heating pads, tea, exercise, and
herbs are already used by women with
menstrual pain.10 Therefore an addi-
tional nondrug and self-care treatment
option might ﬁt well into women’s
perceptions of how to treat menstrual
pain39 and might further support self-
empowerment of affected women.
In our trial, for self-care acupressure,
the effect increased over time, showing
clinical relevance on the pain scale after227.e8 American Journal of Obstetrics& Gynecol6 cycles34 and a responder rate of about
60%. A similar increase was also shown
by a trial from Chen et al.19 However,
most trials on acupressure and
dysmenorrhea have had shorter follow-
ups.14 The ﬁndings that the adherence
was still high after 3 months and that the
effect increased over time are encour-
aging. Regarding the high prevalence of
menstrual pain, a treatment option with
a modest-to-moderate effect and a good
safety proﬁle might have a considerable
public health impact and should be
further evaluated. It would be interesting
to compare app-based self-acupressure
with other active treatment in future
research.
To conclude, self-acupressure sup-
ported and evaluated by a smartphone
app was able to achieve a sustainable
reduction in pain and medication in
comparison to usual care. This self-care
intervention showed a high retention rate
and was safe. We suggest that future trials
should provide long-term data and
compare acupressure with other active
treatments options among a more diverse
target group. nogy FEBRUARY 2018Acknowledgments
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